This past fall, the National Institutes of Health, the Food and Drug Administration and other partners launched the Bespoke Gene Therapy Consortium in an effort to leverage adeno-associated viruses as vectors to treat rare diseases. The initiative seeks to streamline research to clinical use, driving efficiencies into the traditional research and development process. FDA leader Peter Marks and NIH’s P.J. Brooks discuss the consortium’s work and how it aims to help people with rare diseases.
HealthCast
Season 2
Episode 39
21m listen
Gene Therapy is Fighting Rare Diseases in FDA, NIH Program
The technique aims to treat some diseases by gene replacement.
-
Dr. Peter Marks Director CBER, FDA
-
P.J. Brooks Deputy Director, Office of Rare Diseases Research NCATS, NIH
Related Content
-
OPM Navigates AI Governance Through People
OPM's Taka Ariga explores AI's role in an efficient federal workforce and operations, focusing on trust, data integrity and storytelling.
19m listen -
HHS CIO Eyes Special Cyber Measures to Secure Data
Data security and customer experience are top priorities for Jennifer Wendel, the newly confirmed permanent CIO at the Department of Health and Human Services (HHS).
25m listen -
Coming Soon: AI GovCast Season 2 Explores Federal Artificial Intelligence
The first season of AI GovCast brought listeners the voices at the forefront of government's AI revolution. Coming Jan. 14, season two will dive deeper into AI governance, use cases and implementation.
1m listen -
CMS Cyber Integration Center Leverages PenTesting to Protect Patient Data
Testing efforts help better identify vulnerabilities, coordinate incident response and mitigate risks.
15m listen